Tony Mok - AstraZeneca PLC Non-Executive Independent Director
AZN Stock | USD 70.13 1.58 2.30% |
Director
Prof. Tony S. K. Mok is NonExecutive Independent Director of the Company. Professor Tony S K Mok was trained at the University of Alberta, Canada and subsequently completed a fellowship in medical oncology at the Princess Margaret Hospital in Toronto. After working as a community oncologist in Toronto, Canada for seven years, he returned to Hong Kong in 1996 to pursue an academic career. Professor Mok is the Li Shu Fan Medical Foundation endowed Professor and Chairman of the Department of Clinical Oncology at the Chinese University of Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He was the principal investigator and first author on the landmark Iressa PanAsia Study, which was the first trial that confirmed the application of precision medicine for advanced lung cancer. He has led and coled multiple other international Phase III trials, addressing various aspects of the management of advanced lung cancer. His work also includes clinical research on oncogene driven lung cancer and immunotherapy and he contributes to the development of clinical research infrastructure in China and Asia. He cofounded the Lung Cancer Research Group, the Chinese Thoracic Oncology Research Group and the Asia Thoracic Oncology Research Group. Professor Mok has contributed to over 250 articles in international peerreviewed journals, including the New England Journal of Medicine, Science, Lancet, Nature Medicine and Journal of Clinical Oncology, and published multiple editorials and textbooks. He is the pastPresident and current Treasurer of the International Association for the Study of Lung Cancer and serves on the Board of Directors of the American Society of Clinical Oncology . since 2019.
Tenure | 5 years |
Address | 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA |
Phone | 44 20 3749 5000 |
Web | https://www.astrazeneca.com |
AstraZeneca PLC Management Efficiency
The company has Return on Asset of 0.066 % which means that on every $100 spent on assets, it made $0.066 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1564 %, implying that it generated $0.1564 on every 100 dollars invested. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of April 2024, Return On Assets is likely to grow to 0.10, while Return On Tangible Assets are likely to drop 0.11. At this time, AstraZeneca PLC's Tangible Asset Value is very stable compared to the past year. As of the 23rd of April 2024, Intangibles To Total Assets is likely to grow to 0.60, while Total Current Assets are likely to drop about 15.3 B.Similar Executives
Showing other executives | DIRECTOR Age | ||
David Anstice | Alkermes Plc | 69 | |
Paul Mitchell | Alkermes Plc | 64 | |
Edward Kay | Eagle Pharmaceuticals | N/A | |
Alain Schreiber | Eagle Pharmaceuticals | 58 | |
Robert Breyer | Alkermes Plc | 73 | |
Wendy Dixon | Alkermes Plc | 62 | |
Floyd Bloom | Alkermes Plc | 80 | |
Michael Graves | Eagle Pharmaceuticals | 61 | |
Nancy Snyderman | Alkermes Plc | 66 | |
Grainne Troute | Evotec SE ADR | N/A | |
Richard Edlin | Eagle Pharmaceuticals | 57 | |
Steven Ratoff | Eagle Pharmaceuticals | 81 | |
Nancy Wysenski | Alkermes Plc | 60 | |
Robert Glenning | Eagle Pharmaceuticals | 57 | |
David Pernock | Eagle Pharmaceuticals | 63 | |
Hamish Stevens | Evotec SE ADR | N/A | |
Norah Barlow | Evotec SE ADR | N/A | |
Anthony Quirk | Evotec SE ADR | N/A | |
Douglas Braunstein | Eagle Pharmaceuticals | 57 | |
Lynda Reid | Evotec SE ADR | N/A | |
Sander Flaum | Eagle Pharmaceuticals | 81 |
Management Performance
Return On Equity | 0.16 | ||||
Return On Asset | 0.066 |
AstraZeneca PLC ADR Leadership Team
Elected by the shareholders, the AstraZeneca PLC's board of directors comprises two types of representatives: AstraZeneca PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AstraZeneca. The board's role is to monitor AstraZeneca PLC's management team and ensure that shareholders' interests are well served. AstraZeneca PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AstraZeneca PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
Marc Dunoyer, Chief Financial Officer, Executive Director | ||
Sherilyn McCoy, Non-Executive Independent Director | ||
Genevieve Berger, Non-Executive Independent Director | ||
Luke Miels, Executive Vice-President GPPS | ||
Sean Bohen, Chief Medical Officer, Executive Vice President - Global Medicines Development | ||
Paul Hudson, Executive Vice President North America | ||
Nazneen Rahman, Non-Executive Independent Director | ||
Jose Baselga, Executive Vice President - Research & Development Oncology | ||
JeanPhilippe Courtois, Non-Executive Independent Director | ||
Deborah Eldracher, Non-Executive Independent Director | ||
Thomas Larsen, IR Contact Officer | ||
Katarina Ageborg, Executive Vice President - Sustainability, Chief Compliance Officer | ||
Tony Mok, Non-Executive Independent Director | ||
Mark Mallon, Executive Vice President International | ||
Fiona Cicconi, Executive Vice President - Human Resources | ||
Deborah DiSanzo, Non-Executive Independent Director | ||
Chris Sheldon, Head Relations | ||
Shriti Vadera, Non-Executive Independent Director | ||
Leif Johansson, Non-Executive Independent Chairman of the Board | ||
Leon Wang, Executive Vice President - International and China President | ||
Ann Cairns, Non-Executive Director | ||
Adrian Kemp, Company Secretary | ||
Cornelia Bargmann, Non-Executive Director | ||
Susan MD, Executive Development | ||
Tim JacksonSmith, Non-Executive Director | ||
Michel Demare, Non-Executive Independent Director | ||
Graham Chipchase, Senior Non-Executive Independent Director | ||
David Smith, Executive VP of Operations and Information Services | ||
Pascal Soriot, CEO, Executive Director and Member of Disclosure Committee | ||
Pam Cheng, Executive Vice-President of Operations and Information Technology | ||
Baroness Vadera, Non-Executive Independent Director | ||
MBA DVM, CEO Director | ||
Aradhana MD, CFO Director | ||
Philip Broadley, Non-Executive Independent Director | ||
Narayan Seshadri, Independent Director | ||
Jeffrey Pott, General Counsel | ||
Ruud Dobber, Executive Vice President, BioPharmaceuticals Business | ||
David Fredrickson, Executive Vice-President Global Head Oncology Business Unit | ||
Gonzalo Vina, Head Relations | ||
Andrew Barnett, Head Relations | ||
Bahija Jallal, Executive Vice President MedImmune | ||
Rudolph Markham, Non-Executive Independent Director | ||
Menelas Pangalos, Executive Vice President - Research & Development BioPharmaceuticals | ||
Weiying Wang, Non-Executive Director | ||
Bruce Burlington, Non-Executive Independent Director | ||
Marcus Wallenberg, Non-Executive Director | ||
Iskra Reic, Executive Vice President - Europe and Canada |
AstraZeneca Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AstraZeneca PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.16 | ||||
Return On Asset | 0.066 | ||||
Profit Margin | 0.13 % | ||||
Operating Margin | 0.17 % | ||||
Current Valuation | 130.08 B | ||||
Shares Outstanding | 3.1 B | ||||
Shares Owned By Institutions | 16.80 % | ||||
Number Of Shares Shorted | 7.66 M | ||||
Price To Earning | 103.39 X | ||||
Price To Book | 5.46 X |
Pair Trading with AstraZeneca PLC
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AstraZeneca PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will appreciate offsetting losses from the drop in the long position's value.Moving together with AstraZeneca Stock
0.71 | DYAI | Dyadic International Financial Report 8th of May 2024 | PairCorr |
Moving against AstraZeneca Stock
0.74 | DNA | Ginkgo Bioworks Holdings Financial Report 8th of May 2024 | PairCorr |
The ability to find closely correlated positions to AstraZeneca PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AstraZeneca PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AstraZeneca PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AstraZeneca PLC ADR to buy it.
The correlation of AstraZeneca PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AstraZeneca PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AstraZeneca PLC ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AstraZeneca PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the AstraZeneca PLC ADR information on this page should be used as a complementary analysis to other AstraZeneca PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for AstraZeneca Stock analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis View fundamental data based on most recent published financial statements | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Transaction History View history of all your transactions and understand their impact on performance | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Equity Valuation Check real value of public entities based on technical and fundamental data |
Is AstraZeneca PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.059 | Dividend Share 2.9 | Earnings Share 1.91 | Revenue Per Share 2.4547 | Quarterly Revenue Growth 0.073 |
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.